Arbutus Biopharma
ABUS
ABUS
88 hedge funds and large institutions have $227M invested in Arbutus Biopharma in 2018 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
88
Holders Change
+17
Holders Change %
+23.94%
% of All Funds
2.02%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
26
Increased
25
Reduced
21
Closed
9
Calls
$1.82M
Puts
$1.58M
Net Calls
+$241K
Net Calls Change
-$839K
Top Buyers
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$11.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.7M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$3.49M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$3.24M |
| 5 |
Morgan Stanley
New York
|
+$2.74M |
Top Sellers
| 1 |
RI
RTW Investments
New York
|
-$10.2M |
| 2 |
D.E. Shaw & Co
New York
|
-$3.87M |
| 3 |
Goldman Sachs
New York
|
-$2.48M |
| 4 |
Renaissance Technologies
New York
|
-$1.91M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.71M |
